Akums Drugs and Pharmaceuticals Limited — Important, 08-08-2026: Updates

Akums' Board approved Q1 results. All ₹642.18 Cr IPO proceeds are now fully utilized. A subsidiary acquired Oriflame India's manufacturing biz for ₹56.00 Cr, boosting cosmetics, skincare, & wellness capacity. ₹3/share dividend declared. Tax demands (₹60.09 Cr standalone, ₹156.02 Cr consolidated) are under appeal; management expects no material impact.